Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
TLDR
It is concluded that the direct binding of inhibitors to nucleic acids mask their TLR-binding epitope and may explain the efficiency of those compounds in the treatment of autoimmune diseases.Abstract:
Endosomal TLRs play an important role in innate immune response as well as in autoimmune processes. In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time. Their suppression of endosomal TLR activation has been attributed to the inhibition of endosomal acidification, which is a prerequisite for the activation of these receptors. We discovered that chloroquine inhibits only activation of endosomal TLRs by nucleic acids, whereas it augments activation of TLR8 by a small synthetic compound, R848. We detected direct binding of antimalarials to nucleic acids by spectroscopic experiments and determined their cellular colocalization. Further analysis revealed that other nucleic acid-binding compounds, such as propidium iodide, also inhibited activation of endosomal TLRs and colocalized with nucleic acids to endosomes. We found that imidazoquinolines, which are TLR7/8 agonists, inhibit TLR9 and TLR3 even in the absence of TLR7 or TLR8, and their mechanism of inhibition is similar to the antimalarials. In contrast to bafilomycin, none of the tested antimalarials and imidazoquinolines inhibited endosomal proteolysis or increased the endosomal pH, confirming that inhibition of pH acidification is not the underlying cause of inhibition. We conclude that the direct binding of inhibitors to nucleic acids mask their TLR-binding epitope and may explain the efficiency of those compounds in the treatment of autoimmune diseases.read more
Citations
More filters
Journal ArticleDOI
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.
Eva Schrezenmeier,Thomas Dörner +1 more
TL;DR: Mechanistic data give insights into the immunomodulatory potency of hydroxychloroquine and provide the rationale to search for more potent and/or selective inhibitors in antimalarial drugs.
Journal ArticleDOI
Emerging Role of Endosomal Toll-Like Receptors in Rheumatoid Arthritis
TL;DR: The development of therapeutics to inhibit the endosomal TLRs or components of their signaling cascades may represent a way to target inflammation upstream of cytokine production, allowing for greater specificity than existing therapies including cytokine blockade.
Journal ArticleDOI
Systemic lupus erythematosus.
Arvind Kaul,Caroline Gordon,Mary K. Crow,Zahi Touma,Murray B. Urowitz,Ronald F van Vollenhoven,Guillermo Ruiz-Irastorza,Graham R. V. Hughes +7 more
TL;DR: The 10-year mortality has improved and toxic adverse effects of older medications such as cyclophosphamide and glucocorticoids have been partially offset by newer drugs such as mycophenolate mofetil and glucose-sparing regimes.
Journal ArticleDOI
The Pathogenesis of the Antiphospholipid Syndrome
TL;DR: The antiphospholipid syndrome is a prothrombotic disorder associated with autoantibodies associated with obstetrical complications as well as venous and arterial thrombosis risks.
Journal ArticleDOI
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Yvan Jamilloux,Yvan Jamilloux,Thomas Henry,Alexandre Belot,Sébastien Viel,Maxime Fauter,Thomas El Jammal,Thierry Walzer,Bruno François,Pascal Sève +9 more
TL;DR: This review provides an overview of current knowledge on COVID-19 immunopathology, discussing the defective type-I IFN response, the theoretical role of IL-7 to restore lymphocyte repertoire, as well as reviewing current evidence drawn from clinical trials.
References
More filters
Journal ArticleDOI
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.
Hiroaki Hemmi,Tsuneyasu Kaisho,Osamu Takeuchi,Shintaro Sato,Hideki Sanjo,Katsuaki Hoshino,Takao Horiuchi,Hideyuki Tomizawa,Kiyoshi Takeda,Shizuo Akira +9 more
TL;DR: It is shown that the imidazoquinolines activate immune cells via the Toll-like receptor 7 (TLR7)-MyD88–dependent signaling pathway, and that neither MyD88- nor TLR7-deficient mice showed any inflammatory cytokine production by macrophages, proliferation of splenocytes or maturation of dendritic cells.
Journal ArticleDOI
Acidification of the endocytic and exocytic pathways
TL;DR: The Exocytic Pathway and the CharacTERISTICS of PROTON ATPases are reviewed.
Journal ArticleDOI
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Elizabeth A. Leadbetter,Ian R. Rifkin,Andreas Hohlbaum,Britte C. Beaudette,Mark J. Shlomchik,Ann Marshak-Rothstein +5 more
TL;DR: It is shown that effective activation of RF+ B cells is mediated by IgG2a–chromatin immune complexes and requires the synergistic engagement of the antigen receptor and a member of the MyD88-dependent Toll-like receptor (TLR) family.
Journal ArticleDOI
Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.
TL;DR: Results suggest that the vacuolar type H(+)-ATPase plays a pivotal role in acidification and protein degradation in the lysosomes in vivo.
Journal ArticleDOI
Toll-like receptors in systemic autoimmune disease
TL;DR: Data are beginning to emerge showing that this is the case that in vivo activation of both autoreactive B cells and plasmacytoid dendritic cells by mammalian TLR ligands translates to an in vivo role in either the initiation or the progression of systemic autoimmune disease.